At a glance
ClinicalIndex Comparison Record- ✓Multiple myeloma patients who are untreated, asymptomatic, without serious complications, OR have relapsed/failed conventional therapy
- ✓Adequate hematologic, renal, and hepatic functions
- ✓ECOG performance status 0, 1, or 2
- ✕Treatment-naïve patients with high tumor mass or symptomatic/impending fractures
- ✕Significant cardiac disease
- ✕Comorbid conditions conferring high risk of treatment complications
- ✕History of significant neurological or psychiatric disorders
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pilot Study of Curcumin (Diferuloylmethane Derivative) With or Without Bioperine in Patients With Multiple Myeloma
In Brief
A clinical study evaluating Curcumin and Bioperine for Multiple Myeloma. Completed, enrolled 42 participants across 1 site.
Detailed Summary
Primary Objectives: 1. To evaluate clinical tolerance and response to curcumin alone and in combination with Bioperine in patients with multiple myeloma. 2. To compare the pharmacokinetics and pharmacodynamics of curcumin and curcumin + Bioperine and evaluate the effect of Bioperine on the bioavailability of curcumin. 3. To evaluate the biologic effects of curcumin alone and in combination with Bioperine on the expression of NF-kB and related genes in the Multiple Myeloma (MM) cells.
Study Details
Timeline
Interventions
2 grams (Capsules) orally in 2 divided doses (a.m., p.m.)
5 mg (Tablets) orally twice daily